With 25 years of experience in the consumer health care industry, Andrew Scorey joins Chr. Hansen as Senior Vice President, Human Health.
New and exciting opportunities are emerging in
this breakthrough area
Natural solutions that advance human health are in high demand and the expected growth for microbial solutions in this industry is 7-9%. Chr. Hansen is the world’s leading supplier of probiotics to dietary supplements, infant formula and dairy, and through the acquisition of the LGG® business, the company is now further strengthening its microbial platform across all three categories.
在2016年6月21-23日在匈牙利布达佩斯举办的IPC（国际益生菌和益生元科学研讨会）上，人类健康发现(Human Health Discovery)部门的首席科学家Thomas D. Leser展示了关于我们的一些最新的益生菌研究海报。
Our probiotic drops are a convenient solution for infants and young children - safe, easy to dose and can be stored at room temperature (25°).
Add value to your brand with Probio-Tec® probiotics.
The BB-12® probiotic strain was introduced to the market in 1985. Today approx. 200 million people eat products, containing this particular probiotic strain. Eric Johansen is Associate Vice President, Science, at Chr. Hansen.
Today, Chr. Hansen and Caelus Health announce their collaboration on the development of Eubacterium hallii as a next generation probiotic for prevention and treatment of metabolic disease.
Millions of people around the world suffer from a range of gastrointestinal symptoms. Results from one of the world’s largest clinical studies on probiotics now show that the probiotic strain named BB-12® can be part of the solution by improving bowel regularity.
A study initiated by Chr. Hansen has shown that bifidobacteria and lactobacilli are present in breast milk from Chinese mothers, strengthening the case for adding clinically documented probiotics to infant formula, in order to improve nutrition.
Establishes a new research and development consortium and secures access and commercialization rights to an important resource of strains